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Abstract: Despite the development of a large number of promising
candidates, few contrast agents for established medical imaging modalities
have successfully been translated over the past decade. The emergence of
new imaging contrast agents that employ biomedical optics is further
complicated by the relative infancy of the field and the lack of approved
imaging devices compared to more established clinical modalities such as
nuclear medicine. Herein, we propose a navigational approach (as opposed
to a fixed “roadmap”) for translation of optical imaging agents that is
(i) proposed through consensus by four academic research programs that are
part of the cooperative U54 NCI Network for Translational Research,
(ii) developed through early experiences for translating optical imaging
agents in order to meet distinctly varied needs in cancer diagnostics, and
(iii) adaptable to the rapidly changing environment of academic medicine.
We describe the pathways by which optical imaging agents are synthesized,
qualified, and validated for preclinical testing, and ultimately translated for
“first-in-humans” studies using investigational optical imaging devices. By
identifying and adopting consensus approaches for seemingly disparate
optical imaging modalities and clinical indications, we seek to establish a
systematic method for navigating the ever-changing “roadmap” to most
efficiently arrive at the destination of clinical adoption and improved
outcome and survivorship for cancer patients.
© 2012 Optical Society of America
OCIS codes: (170.0170) Medical optics and biotechnology; (170.3880) Medical and biological
imaging; (170.3890) Medical optics instrumentation.
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1. Introduction
Biomedical optical imaging technologies have substantive potential for revolutionizing cancer
diagnosis, staging, treatment and survivorship, but translation of these technologies from the
academic research laboratories into academic medicine is stymied by the lack of a “model” or
“roadmap”. Since there have been few targeted optical imaging agents that have been
successfully translated, there is a need to chart the translational pathway. “First-in-humans”
studies of optical imaging agents are needed for initial demonstration of potential clinical
utility, but this uncharted territory is further complicated by the lack of appropriate imaging
instruments that are approved for clinical use. Regulatory pathways that require combinational
drug (contrast agent) approval from Center for Drug Evaluation and Research (CDER) or
Center for Biologics Evaluation and Research (CBER), and device approval (imaging
instrument) from Center for Devices and Radiological Health (CDRH), comprise one of the
requisite steps in translation that can be more substantial if the synthesis, validation, and
qualification of an imaging agent is conducted independently from its respective
investigational imaging device. The Chemistry Probes and Guided Therapies Core working
group of the NCI Network of Translational Research (NTR) is charged with describing the
development of optical imaging agents within the context of the diverse translational optical
imaging projects in each of the NTR Centers (comprised of Stanford University (SU),
University of Michigan (UM), Washington University at St. Louis (WUSTL), and the
University of Texas Health Science Center (UTHSC)), and sharing common experiences to
accelerate the translation of optical imaging agents. The NTR is the second of two consecutive
programs in the NCI Cancer Imaging portfolio that seeks to translate imaging technologies. In
its first NCI U54 program (2003-2008), the Network for Translational Optical Imaging
(NTROI) focused upon translating optical devices while the current NTR (2008-2013) focuses
upon translating optical imaging devices and imaging agents together with a conventional
imaging modality to provide embedded validation.
2. NTR translational projects
As a means of introduction, Table 1 provides a listing of the device platform/modality,
proposed imaging agent, and unmet clinical need addressed in each of the NTR projects. Not
all biomedical optical imaging modalities are presented within the NTR, but all possess the
translation of a combinational drug/device in some type of hybrid imaging approach that
could lend further validation through comparative efficacy studies. Initially, each team is
advancing combinations of contrast agents and instruments for very specific unmet clinical
needs, however, each set of technologies is designed to have broader clinical utility thereafter
and are described briefly below.
SU employs next generation, multi-wavelength, fiber-optic fluorescent micro-endoscopes
for gastrointestinal screening of high-risk populations. Their technology development targets a
high-risk population with hereditary diffuse gastric cancer (HDGC), which is an autosomal
dominant cancer susceptibility syndrome caused by germline mutations in E-cadherin
(CDH1). Without standard-of-care, prophylactic gastrectomy, subjects with HDGC
experience an 80% lifetime risk of developing, and dying from, gastric cancer. The
translational paradigm of SU focuses upon conducting esophagogastroduodenoscopy in these
patients using wide-field fluorescence endoscopes (macroscopic) and miniaturized dual-axis
confocal microscopes (microscopic) [1,2] for interrogation of fluorescence following
intravenous (i.v.) administration of a “first-in-humans” imaging agent, fluorocoxib, that was
developed in collaboration with Vanderbilt University (VU) to target cyclooxygenase-2
(COX-2) [3]. The off-label use of indocyanine green (ICG) comprises a first step toward
translation enabling validation of the microendoscope prior to deploying the COX-2 agent.
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Table 1. Overview of NTR teams and research strategies
Research
Team

Program Title

SU

Multimodal
Imaging of
GI Cancers
for Diagnosis
and Directed
Therapy

UM

In Vivo Detection
of Neoplasia in
the Digestive
Tract

WUSTL

UTHSC

Technology
development
strategy
• Endoscopy
• Fluorescently
labeled COX-2
targeting probes

Disease models
investigated

Clinical Need/Relevance

Gastrointestinal
tract cancers

• Molecularly guided detection
of neoplasia in the GI is
non-existent
• Optical imaging at time of
visual endoscopy will improve
sensitivity of endoscopic
detection in high risk cases

• Multi-spectral
endoscopy
• Fluorescently
labeled peptides

Colonic
neoplasia

• Molecularly guided detection
of neoplasia in the colon is
non-existent
• Fluorescence molecular
imaging at time of visual
endoscopy will improve
sensitivity of endoscopic
detection in high risk cases

Photoacoustic/
Optical/
Ultrasonic
Imaging of
Sentinel Lymph
Nodes and
Metastases

• Photoacoustic
and diffuse
optical
tomography
• Dual-labeled
imaging probes

LN mapping in
breast cancer

• PAT techniques offer a high
resolution, non-ionizing
method for detecting SLNs
• Ability to combine the
sensitivity/specificity of optical
imaging with depth and
resolution of ultrasound

Diagnostic Nodal
Staging with
Nuclear and NIR
Molecular
Optical Imaging

• NIRF imaging
• Dual-labeled
imaging probes

Lymphatic
imaging and LN
detection in
cancer

•NIR fluorescence provides a
rapid method for visualizing
the lymphatic function
architecture not possible with
lymphoscintigraphy
•Dual-labeled imaging agents
targeting cancer in LNs lymph
nodes provide non-invasive
TNM staging through whole
body and intraoperative
imaging.

The translational paradigm at UM involves combination instruments for fluorescent
colonoscopy in high-risk individuals diagnosed with familial adenomatous polyposis (FAP)
and hereditary nonpolyposis colorectal cancer (HNCPP, Lynch Syndrome). In their proposed
“first-in-humans” studies, peptides discovered through phage display technologies are labeled
with fluorescein isothiocyanate (FITC), a derivative of the green fluorophore, fluorescein,
which is already used in humans. These are designed for topical administration and to bind to
luminal intestinal surfaces of dysplastic mucosa to enable early detection and screening in
high-risk populations [4–6].
WUSTL has focused on translation of photoacoustic tomography (PAT) which
significantly increases the effective depth of optical contrast detection [7]. Pre-operative PAT
detects uptake of off-label intradermal administration methylene blue (MB) and ICG in order
to perioperatively identify sentinel lymph nodes (SLNs) in breast cancer patients [8]. Off-label
use of approved agents accelerates the deployment of the PAT imaging device in human
studies. Novel multimodal agents are also under development to enable hybrid imaging using
PAT/fluorescence/nuclear imaging and include (i) a derivative of ICG that can be conjugated
to a chelating agent for radiometal sequestration, (ii) MB with isotopic Iodine-125 labeling
[9], and (iii) functionalized nanoparticles for targeted, molecular imaging using PAT, nuclear,
and fluorescence imaging approaches [10–12]. This multimodal approach provides means for
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validation of PAT with standard-of-care gamma scintigraphy or Single-Photon Emission
Computed Tomography (SPECT) for SLN mapping, as well as future molecular imaging
applications.
Finally, the UTHSC primary project focuses upon the development of multimodal “firstin-humans” imaging agents possessing a radiolabel and a near-infrared (NIR) fluorophore to
permit non-invasive imaging of lymph node (LN) status, and intraoperative imaging of
cancer-positive LNs and tumor margins during surgery. In preparation for the clinical
evaluation of novel multimodal imaging agents, their team used an off-label, intradermal
administration of ICG at microdoses to qualify their investigational, military-grade intensified
charge-coupled device (CCD) camera in Phase I/II Investigational New Drug (IND) clinical
studies [13,14]. “First-in-humans” targeting vectors under investigation at UTHSC consist of
(i) a well-established peptide targeting the somatostatin receptor (SSTR) in neuroendocrine
tumors (NETs) and (ii) affinity matured monoclonal antibodies (mAbs) or mAb-based
fragments targeting epithelial cell adhesion molecule (EpCAM) [15,16], a protein almost
universally overexpressed on the surface of cancer epithelial cells. Dual labeling strategies are
based on innovative multimodality chelators which minimally affect the biological and
pharmacokinetic (PK) properties of targeting agents.
3. Navigational pathway
Certain members from each of the NTR teams constituted the Chemistry Probes and Guided
Therapies Core and have devised logical pathways for target identification (where applicable),
design and synthesis of agents, production, batch release, validation, and subsequent
deployment in both preclinical and investigational human studies (Fig. 1).

Identify
Target

Expressed in
clinical
samples

Expressed on
cells

Extracellular
or
intracellular?

Expressed in
animal model
for testing?

Synthesis
of Agent

Targeting
strategy

Biological
activity

PK, BD

Route of
admin, dose

Production

Ease/cost of
preparation

Reproducible

Well defined
composition

Stability,
packaging,
storage

Batch
Release

Identity and
purity

Sterility and
pyrogenicity

Biological and
optical
activity

Concentration,
radiolabeling
efficiency and
purity

Validation

Preclinical
small animal
models

Veterinary
applications

Comparative
medical
applications

Phase 0/I
investigatory
studies

Fig. 1. Pathways for developing and validating a molecular imaging agent (BD =
biodistribution).

Once beyond the agent discovery and development stages, the next three steps of
synthesis, production, and batch release are defined strictly in a standard operating procedure
(SOP). SOPs are critical for the subsequent translational phase wherein production steps and
analytical assays for batch release are replicated, validated, and conducted under good
laboratory practice (GLP) and typically include certificates of analysis for all reagents,
calibration and maintenance logs for all equipment used, audit trails, and defined packaging
and storage conditions that ensure validated stability. Examples of navigational pathways for
the four NTR Centers are represented herein as agent development flowcharts.
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3.1. SU/VU agent development approach
At SU, the focus has been on a single molecular probe, fluorocoxib (Fig. 2). The rationale for
probe selection was to select a high-value imaging target that would have the greatest impact
on early detection, guided resection, and prognosis, and to provide an outcome measure for a
range of malignancies using a single molecule [17]. Based on the association of chronic
inflammation with neoplasia and increased activity of the intracellular enzyme COX-2, the
SU/VU collaboration identified several well-characterized COX-2 inhibitors as candidates for
a molecularly target optical imaging agent. By employing various combinations of linkers and
fluorophores during the agent synthesis process, they were able to generate a library of agents
for subsequent evaluation. Since commercially available reagents and dyes may not always
address specific needs for given molecule, the SU/VU collaboration provided the know-how
to perform custom syntheses in-house and greatly enhanced the flexibility of agent design
strategies. Ultimately, fluorocoxib was prepared by fluorescently labeling the COX-2
inhibitor, indomethacin, and validated preclinically in vitro and in tumor-bearing animals. The
in vivo imaging studies with fluorocoxib also allowed the investigators to define detection
limits of the instrument as an added characterization step. By successfully demonstrating
efficacy for tumor targeting with acceptable PK, the good manufacturing practice (GMP)
synthesis, optimization of formulation, and toxicological testing were outsourced to a contract
facility to complete the required preclinical characterization steps and initiate preparation of
the IND application.

Fig. 2. Screening and development of the COX-2 targeted agent, fluorocoxib by SU/VU.

3.2. UM agent development approach
For UM, the discovery process begins with target identification and peptide selection from
screening phage libraries (Fig. 3).
Solid phase synthesis with on-column fluorescent label conjugation enables precise
labeling and composition that is characterized by mass spectrometry (MS), high-performance
liquid chromatography (HPLC), and optical property measurements prior to being
characterized for biological activity by a validated assay. If characterization of composition
and biological activity meets a minimal, acceptable, but clearly defined criteria, the agent is
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precisely formulated in its delivery vehicle before undergoing preclinical testing of efficacy
with a designated imaging device. If successful, then the manufacturing plan is devised using
GMP and the Chemistry, Manufacturing and Controls (CMC) section (which includes
production, analytical testing, and batch release criteria) of an IND application is prepared.
For a fluorescently labeled peptide such as that under development by UM, batch release

Fig. 3. Flowchart for screening, selection, preparation, and characterization of fluorescent
peptide probes at UM.

criteria should include optical property measurements of extinction coefficient, fluorescent
yield (quantum efficiency), and lifetime. Efficacy of resulting peptide agents are typically
tested using scrambled or non-scrambled peptides in vitro as well as in vivo to establish
potential utility and molecular specificity.
3.3. WUSTL agent development approach
Investigators at WUSTL have focused on translation of a clinical PAT device with off-label
use of darkly colored dyes such as MB and ICG. PAT contrast is based on optical absorption
and detection of ultrasound generation rather than fluorescence. Thus PAT enables detection
of optical agents several centimeters below the skin surface. As a means of validating clinical
PAT devices and pushing the boundaries of optical molecular imaging, WUSTL is also
developing an array of agents that generate multiple contrast modes to combine optical
imaging (PAT or Diffuse Optical Tomography (DOT)) with nuclear imaging (SPECT or
Positron Emission Tomography (PET)). Isotopically labeled Iodine-125 MB may be used for
whole-body SPECT/CT to validate SLN identification by PAT. Cypate, a functionalizable
analog of ICG, possesses a high extinction coefficient for excellent PAT contrast as well as
good quantum yield for fluorescence imaging. Conjugation of tyrosine for radio-iodination or
a chelator for sequestration of radiometals enables combinations of PAT and DOT with
SPECT (Indium-111) or PET (Copper-64). These agents provide non-specific lymph node
mapping while other agents that are conjugated to targeting moieties will enable specificity to
cancer.
At the initial optical reporter discovery step depicted in Fig. 4, NIR reporters are sought
due to the relative transparency of biological tissues in this light region and are needed to
enable greatest tissue penetration and largest detectable PAT signal. Functionalizable NIR
contrast agents with high absorption coefficients demonstrate a broad range of possibilities for
molecular imaging contrast and potential for clinical applications of PAT.
The development of the PAT dye with a functional group for conjugation to a chelator or
targeting moiety is then decided. Whether using isotopic substitution or a chelated radiometal,
radiolabeling of the final conjugate requires testing for labeling efficiency, radiochemical
purity, and stability of the agent. Assessment of composition and possible alteration of optical
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properties under the sometimes harsh radiolabeling conditions are then evaluated through
HPLC, as well as measurement of optical properties. After formulation to the correct dosage,
the in vivo efficacy of the probe is evaluated to assess the PK for reaching sentinel and
subsequent LNs within the draining basin. If the agent provides adequate signal with a
reasonable PK profile, it is then considered for further development, including stability
testing, GMP production, GLP safety and toxicity testing, and eventually, investigational
studies in humans.

Fig. 4. Flowchart for synthesis and characterization multimodal agents for SLN mapping by
WUSTL.

3.4. UTHSC agent development approach
The translational paradigm at UTHSC is twofold. First, the team engineers unique mAbs and
mAb fragments with maximal affinity which contain chemical modifications to modulate PK
and reactive groups introduced away from binding domain for site specific conjugation of a
chelator, NIR fluorophore, or a customized multimodality chelator. In a second
complementary approach, they conjugate a selected SSTR-targeting peptide with the
multimodality chelator. As shown in Fig. 5, both cases choose the fluorophore on the basis of
fluorescent properties, size, and stability in selected radiolabeling conditions, whether with
Gallium-68 (t1/2 = 68 min) for rapidly clearing agents (e.g., peptides or mAb fragments), or
Copper-64 (t1/2 = 12.7 h) for agents with longer circulation time (e.g., full-length mAbs).
The resulting chelator, fluorophore, or multimodality chelator conjugate is then
characterized by MS and HPLC, quantitative flow cytometry (for optical assessment), Lindmo
assays (for radioactive assessment), or surface plasmon resonance (for quantifying biological
activity on target expressing cells or target proteins themselves). If biological activity is
quantitatively retained following conjugation(s), then optical properties, radiolabeling
efficiency, and stability are determined before the product is deemed suitable for further
evaluation. The product may then be lyophilized, frozen, or stored at 4°C for subsequent
experiments. Next, in vivo studies are employed to determine if adequate signal is attainable at
microdoses using clinically validated NIRF imaging instrumentation and a standardized PET
imaging scanner [18]. Once validated in animal models, long-term stability testing, GMP
production, GLP safety and toxicity testing are performed, and eventually, investigational
human studies are conducted. It should be noted that the preclinical validation for mAbs
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typically employ isotype mAbs and mAb fragments as well as mAb products which cross
react with both human and mouse targets.
The pathways taken for each team are different, depending upon the translational
objectives, but each focuses upon qualification of the imaging agent on the basis of biological
activity and imaging performance based upon the appropriate criteria (radiolabeling
efficiency, fluorescent yield, absorption coefficient). Eventually, each approach arrives at a
common point which where a GMP compliant manufacturing plan is required in order to gain
approval for human studies.

Fig. 5. Flowchart for preparation and characterization of fluorescent and dual-labeled mAbs by
UTHSC. (D/P = dye/protein ratio, QC = quality control).

4. Anticipate problems in translational research
While these translational studies are underway, findings of potentially confounding
difficulties have been, and will continue to be, encountered as progress is made toward the
clinic. The uncertain pathway provides an additional impetus for our community to share
common experiences that will in turn enable more efficient navigational routes for shared,
effective translation strategies. The first most commonly encountered problem in translation
of optical imaging agents is the lack of well-suited instrumentation, including analytical
equipment that is operational in relevant wavelengths often in the NIR range. While this
deficiency in analytical equipment is lessening with the widespread development and use of
NIR fluorophores with low autofluorescent characteristics, common analytical instruments
such as confocal microscopes, HPLCs, plate readers, flow cytometers, etc., typically require
custom retrofitting with diodes, detectors, filters, and lenses with coatings that enable NIR
interrogation. In addition, conventional endoscopy and intraoperative devices are being or
have been adapted to image ICG, typically administered i.v. and detected at far larger doses
than would be required for the pico- to femto-molar concentrations needed for molecular
imaging. However, promising findings from preclinical research have revealed, in some
applications, complementary data sets obtained with NIR and nuclear imaging [19–22].
Therefore, dual-labeled agents are rapidly being recognized as emerging clinical opportunities
for multimodality validation and development of hybrid agents for diagnostic and
intraoperative imaging [23–25]. It should be noted that Azhdarinia and associates showed that
radiolabeling can alter the fluorescent properties of NIR fluorophores with varying degrees
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based on the harshness of reaction conditions [26]. As a result, the process of choosing a
fluorophore and optimizing radiolabeling conditions must be carefully conducted as indicated
in the agent development flow charts above to ensure that the fluorescent optical properties of
dual-labeled agents are comparable to a (single) fluorescently labeled counterpart.
Another emerging difficulty relates to some of the companies that produce reagent-grade
NIR dyes and have built their business on academic research. Besides the already restrictively
high price for reagent-grade dyes, the requirements of increased pricing for GMP-produced
dyes and “clinical trial agreements” that include intellectual property rights to optical imaging
devices and technologies complicates the translation of NIR conjugates. Moreover, academic
and industrial partners are likely unable to financially and legally agree to such an agreement
making this practice selectively detrimental to the biomedical optics community. Given that
GMP manufacturers of chelators for nuclear imaging do not exhibit the same level of
involvement in the translational use of their reagents, the biomedical optics community may
face significantly larger obstacles when compared to nuclear imaging. As the value
proposition for optical imaging is realized, these relationships may be predicted to evolve and
change rapidly. It is noteworthy that an increasing number of companies are manufacturing
NIR fluorophores at reasonable costs, but not all provide chemical structures and identity
information necessary for incorporation into CMC documentation. As an alternative strategy
to overcome this translational barrier, academic centers could engage in the production of NIR
fluorophores alone or in consortia of academic/industrial partners. Otherwise, it is never too
early to initiate a discussion with the R&D department of a dye manufacturer if one intends to
employ its dye in an imaging agent used in translational studies.
Finally, due to the importance of demonstrating innovation in their individual research
programs, academicians are constantly employing novel reagents, targeting molecules,
chemical compositions, and formulations in their studies. While this accelerates innovation in
the field, it reduces commonality and limits the ability to directly compare and cross-validate
promising preclinical data which may have translational potential. Therefore, consensus
efforts are critical and can add value to the field by identifying general schemes within which
current probe development efforts can be grouped, while also proposing a navigational route
to improve upon existing translational efforts. Academic researchers are not typically focused
on the cumbersome manufacturing process of new imaging agents for clinical trials and may
find themselves facing significant obstacles as promising imaging agents advance toward
human testing. In particular, the development of reproducible and validated synthetic
processes are lacking in academia. As the handoff to a contract manufacturer typically occurs
for GMP manufacturing of a probe, the presence of validated SOPs, batch records, and
analytical data are critical and can facilitate efficient method development and validation by a
contract manufacturer. Accordingly, academic laboratories and consortia would benefit from
developing detailed compound characterization checklists which include standard tests such
as structural confirmation and purity of the probe, but also more extensive analyses of
compound-specific criteria such (i) radiolabeling efficiency of dual-labeled probes, (ii)
stability of i.v. vs. topical formulations, (iii) amenability to processing steps such as
lyophilization, and (iv) effects of storage conditions. Highly rigorous testing in academic
laboratories offers a better likelihood for cross-validation of methods by the outside
manufacturer, and ultimately supports more efficient translational development of a probe.
5. Conclusion and summary
Due to the complexities associated with designing and characterizing a molecular imaging
probe for human use, it is highly beneficial to the research community to share our
experiences in obtaining the necessary know-how and resources to carry the translational
process from beginning to end. Building upon the recent NTR-wide publication by Aldrich et
al. that focused on instrument validation needs of each research team [27], this contribution
stresses the importance of creating consensus efforts to bridge gaps that exist in the
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understanding of the translational process specific to imaging agents. Under our model, there
is constant interaction between the core and advisors in regulatory agencies as well as industry
leaders that are well-versed in translation. Several prominent individuals from imaging-related
pharmaceutical companies participate in defining research strategies and milestones for each
research program to better obtain alignment with industry standards. The direct input is
critical to the success of translating new imaging technologies into the clinic and forms the
basis for the recommendations for best practices set forth by the core. Defining plans for
probe development from the ground up will provide academicians with a more comprehensive
understanding of factors such as milestones, timelines, and expected costs of clinical testing,
which substantially improves the likelihood of success for translating new imaging
technologies into humans.
As alluded to in Section 4, market segmentation can profoundly influence whether a
technology with diverse components can be clinically translated, irrespective of a compelling
case for improved patient outcomes. In the current economic climate, collaborations which
include these diverse markets are critical for a single, shared and focused mission of
technology application for improved patient outcomes. For this case of biomedical optical
imaging, the challenges of focusing the instrumentation and reagent industries on a shared
mission is best met by roadmap objectives since translation and regulatory strategies will
involve not one or the other, but both industries. The roadmap for translating biomedical
optical imaging (both drug and device) requires assessing the shared translational routes for
both instrumentation and reagent industries. Identifying the navigational routes for translating
optical imaging agents and (under the charge of the Instrumentation Core working group of
the NTR) optical imaging devices, enables a better understanding of how these industry
segments can collaborate to realize a new markets to meet unmet clinical needs.
Most importantly, the ability to bring diverse, segmented markets together requires not
only a compelling clinical need, but a compelling market as well. The clinical “impact” of
research and technology developments to solve unmet needs is judged as a criterion on most
research grants. Yet “impact” is not always examined with the consideration of economic or
market limitations as are “market assessments.” In addition, principles of beneficence require
that we engage in clinical research that can benefit populations (whether orphan or not), and
by interference, involve technologies that have either an existing or potential market (whether
large or small). The navigational routes established for both optical imaging devices and
imaging agents enable greater clarity for conducting market assessments that need to be
continually updated along the overall route for translating optical imaging technologies. In
this NTR Chemistry Probes and Guided Therapies Core working group, market assessments
were not part of the general translational roadmap although they were made in varying
degrees by each of the participating centers and partners for their entire technology platforms.
Nonetheless, the clinical impact is significant for cancer patients and survivors who need
image guidance for improved therapy and real-time risk assessment. As a community, we
need to ensure that our discoveries that have clear evidence to fulfill unmet clinical needs
actually translate into the clinic. We may need to pose our discoveries in the context of
existing or new markets and educate both the clinical end-users and the patient population
who can benefit from these advances. Given the number of unmet clinical needs that can be
addressed using optical physics, and the advances in optical instrumentation, there is a bright
future for biomedical optical imaging agents.
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